Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel

Inclusion Criteria:

* Histologically or cytologically documented gynaecologic cancer
* Patients who are chemotherapy naive and scheduled to receive 1-day moderately emetogenic chemotherapy (carboplatin Area under Curve (AUC) 5 plus paclitaxel).
* Women, 18 years and older
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
* Adequate organ system function, defined as follows:

bone marrow: absolute neutrophil count \>=1,500/L, platelets \>=100,000/L liver: bilirubin 1.5 x upper limit of normal (ULN); transaminases \<=2.5 x ULN kidney: creatinine \<=1.5 x ULN

• Able to take oral medications

Exclusion Criteria:

* psychiatric illness or social situation that would preclude study compliance
* history of central nervous system (e.g., brain metastases, seizure disorder)
* Positive pregnancy test just before registration.
* treatment with any anti-emetic medication from 24 hours to 5 days after treatment.
* treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone for 30 days before or during protocol therapy.
* concurrent abdominal radiation therapy.
* concurrent quinolone antibiotic therapy.
* known hypersensitivity to olanzapine.
* vomiting and/or significant nausea (\>= Common Toxicity Criteria for Adverse Events (CTCAE) grade 2) within the 24 hours before beginning chemotherapy.
* another organic cause for nausea or vomiting unrelated to chemotherapy administration.
* chronic alcoholism (as determined by the investigator).
* known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous 6 months.
* history of uncontrolled diabetes mellitus.